{"nctId":"NCT03548935","briefTitle":"STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity","startDateStruct":{"date":"2018-06-04","type":"ACTUAL"},"conditions":["Metabolism and Nutrition Disorder","Overweight or Obesity"],"count":1961,"armGroups":[{"label":"Semaglutide s.c. 2.4 mg once weekly","type":"EXPERIMENTAL","interventionNames":["Drug: Semaglutide"]},{"label":"Semaglutide placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo (semaglutide)"]}],"interventions":[{"name":"Semaglutide","otherNames":[]},{"name":"Placebo (semaglutide)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nMain phase:\n\n* Male or female, age greater than or equal to 18 years at the time of signing informed consent\n* Body mass index (BMI) greater than or equal to 30.0 kg/sqm or greater than or equal to 27.0 kg/sqm with the presence of at least one of the following weight-related comorbidities (treated or untreated): hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease\n* History of at least one self-reported unsuccessful dietary effort to lose body weight\n\nExtension phase:\n\n* Informed consent for the extension phase obtained before any trial related activities for the extension phase\n* On randomised treatment on the target dose at week 68, i.e. treated with 2.4 mg semaglutide once-weekly or semaglutide placebo\n\nExclusion Criteria:\n\nMain phase:\n\n* Glycated haemoglobin (HbA1C) greater than or equal to 48 mmol/mol (6.5%) as measured by the central laboratory at screening\n* A self-reported change in body weight greater than 5 kg (11 lbs) within 90 days before screening irrespective of medical records\n\nExtension phase:\n\n* Female who is pregnant or intends to become pregnant during the extension phase\n* Any disorder, unwillingness or inability, not covered by any of the other exclusion criteria, which in the investigator's opinion, might jeopardise the subject's compliance with the extension of the trial","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Body Weight (%)","description":"Change in body weight from baseline (week 0) to week 68 is presented. The endpoint was evaluated based on the data from both in-trial and on-treatment observation periods. In-trial observation period: the uninterrupted time interval from date of randomization (week 0) to date of last contact with trial site (week 75). On-treatment observation period: includes all time intervals in which participants are considered to be on treatment from the first (week 0) to last trial product administration (week 68), including 2 weeks of follow-up. It excludes any period of temporary treatment interruption. Temporary treatment interruption is defined as more than 2 consecutive missed doses (off-treatment period).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-15.6","spread":"10.1"},{"groupId":"OG001","value":"-2.8","spread":"6.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.9","spread":"9.4"},{"groupId":"OG001","value":"-3.1","spread":"6.4"}]}]}]},{"type":"PRIMARY","title":"Participants Who Achieve 5 or More Percent Body Weight Reduction (Yes/no)","description":"Number of participants who achieved weight loss more than or equal to 5% (yes/no) at week 68 are presented. The endpoint was evaluated based on the data from both in-trial and on-treatment observation periods. In-trial observation period: the uninterrupted time interval from start of randomization (week 0) to last trial-related subject-site contact (week 75). On-treatment observation period: includes all time intervals in which participants are considered to be on treatment from the first (week 0) to last trial product administration (week 68), including 2 weeks of follow-up. It excludes any period of temporary treatment interruption.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1047","spread":null},{"groupId":"OG001","value":"182","spread":null}]},{"measurements":[{"groupId":"OG000","value":"165","spread":null},{"groupId":"OG001","value":"395","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"978","spread":null},{"groupId":"OG001","value":"165","spread":null}]},{"measurements":[{"groupId":"OG000","value":"81","spread":null},{"groupId":"OG001","value":"334","spread":null}]}]}]},{"type":"SECONDARY","title":"Subjects Who Achieve 10 or More Percent Body Weight Reduction (Yes/no)","description":"Number of participants who achieved weight loss more than or equal to (≥) 10% at week 68 is presented. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from date of randomization (week 0) to date of last contact with trial site (week 75).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"838","spread":null},{"groupId":"OG001","value":"69","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"374","spread":null},{"groupId":"OG001","value":"508","spread":null}]}]}]},{"type":"SECONDARY","title":"Participants Who Achieve 15 or More Percent Body Weight Reduction (Yes/no)","description":"Number of participants who achieved more than or equal to (≥) 15% weight loss at week 68 is presented. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from start of randomization (week 0) to last trial-related subject-site contact (week 75).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"612","spread":null},{"groupId":"OG001","value":"28","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"600","spread":null},{"groupId":"OG001","value":"549","spread":null}]}]}]},{"type":"SECONDARY","title":"Participants Who Achieve 20 or More Percent Body Weight Reduction (Yes/no)","description":"Number of participants who achieved more than or equal to (≥) 20% weight loss at week 68 is presented. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from start of randomization (week 0) to last trial-related subject-site contact (week 75).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"388","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"824","spread":null},{"groupId":"OG001","value":"567","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Waist Circumference (cm)","description":"Change in waist circumference from baseline (week 0) to week 68 is presented. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from start of randomization (week 0) to date of last contact with trial site (week 75).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.1","spread":"9.6"},{"groupId":"OG001","value":"-4.4","spread":"6.9"}]}]}]},{"type":"SECONDARY","title":"Change in Systolic Blood Pressure (mmHg)","description":"Change in systolic blood pressure from baseline (week 0) to week 68 is presented. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from start of randomization (week 0) to date of last contact with trial site (week 75).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7","spread":"14"},{"groupId":"OG001","value":"-1","spread":"13"}]}]}]},{"type":"SECONDARY","title":"Change in Short Form 36 (SF-36)","description":"SF-36 is a 36-item patient-reported survey of patient health that measures the participant's overall health-related quality of life (HRQoL). SF-36v2™ questionnaire measured eight domains of functional health and well-being as well as two component summary scores (physical component summary and mental component summary). In the metric of norm-based scores, 50 and 10 corresponds to the mean and standard deviation, respectively, for the 2009 US general population. Change from week 0 in the domain scores and component summary scores were evaluated at week 68. A positive change score indicates an improvement since baseline. These endpoints were evaluated based on the data from in-trial observation period which is the uninterrupted time interval from start of randomization (week 0) to last trial-related subject-site contact (week 75).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":"6.6"},{"groupId":"OG001","value":"0.4","spread":"7.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":"7.2"},{"groupId":"OG001","value":"-0.2","spread":"7.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"8.2"},{"groupId":"OG001","value":"-1.3","spread":"8.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":"7.2"},{"groupId":"OG001","value":"-0.6","spread":"7.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":"8.0"},{"groupId":"OG001","value":"-1.3","spread":"7.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"6.6"},{"groupId":"OG001","value":"-1.4","spread":"7.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.9","spread":"7.3"},{"groupId":"OG001","value":"-1.5","spread":"7.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"7.0"},{"groupId":"OG001","value":"-1.7","spread":"7.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":"6.7"},{"groupId":"OG001","value":"0.2","spread":"7.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.5","spread":"7.1"},{"groupId":"OG001","value":"-2.1","spread":"7.7"}]}]}]},{"type":"SECONDARY","title":"Change in Impact of Weight on Quality of Life-Lite for Clinical Trial (IWQoL-Lite for CT) Score","description":"IWQoL-Lite for CT is a modified version of an instrument designed to assess weight-related quality of life. It is used to assess the impact of body weight changes on patients' physical and psychosocial functioning in three composite scores (physical function, physical and psychosocial) and a total score. The scores range between 0-100 where higher scores indicate a better quality of life. A positive change score indicates an improvement since baseline. These endpoints were evaluated based on the data from in-trial observation period which is the uninterrupted time interval from start of randomization (week 0) to last trial-related subject-site contact (week 75).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.0","spread":"21.6"},{"groupId":"OG001","value":"6.0","spread":"21.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.0","spread":"20.0"},{"groupId":"OG001","value":"5.0","spread":"19.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.4","spread":"19.2"},{"groupId":"OG001","value":"6.9","spread":"17.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.2","spread":"17.8"},{"groupId":"OG001","value":"6.3","spread":"16.8"}]}]}]},{"type":"SECONDARY","title":"Change in Body Weight (kg)","description":"Change in body weight from baseline (week 0) to week 68 is presented. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from start of randomization (week 0) to last trial-related subject-site contact (week 75).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.1","spread":"10.6"},{"groupId":"OG001","value":"-2.9","spread":"7.2"}]}]}]},{"type":"SECONDARY","title":"Change in Body Mass Index (BMI) (kg/m2)","description":"Change in body mass index from baseline (week 0) to week 68 is presented. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from start of randomization (week 0) to last trial-related subject-site contact (week 75).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.8","spread":"3.8"},{"groupId":"OG001","value":"-1.0","spread":"2.5"}]}]}]},{"type":"SECONDARY","title":"Change in HbA1C (%)","description":"Change in glycosylated haemoglobin (HbA1c) from baseline (week 0) to week 68 is presented. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from start of randomization (week 0) to last trial-related subject-site contact (week 75).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"0.3"},{"groupId":"OG001","value":"-0.2","spread":"0.3"}]}]}]},{"type":"SECONDARY","title":"Change in HbA1C (mmol/Mol)","description":"Change in HbA1c from baseline (week 0) to week 68 is presented. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from start of randomization (week 0) to last trial-related subject-site contact (week 75).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.1","spread":"3.3"},{"groupId":"OG001","value":"-1.8","spread":"3.0"}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Plasma Glucose (FPG) (mg/dL)","description":"Change in fasting plasma glucose from baseline (week 0) to week 68 is presented. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from start of randomization (week 0) to last trial-related subject-site contact (week 75).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.2","spread":"10.9"},{"groupId":"OG001","value":"-0.4","spread":"12.7"}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Serum Insulin (mIU/L) - Ratio to Baseline","description":"Change in fasting serum insulin from week 0 to week 68 is presented as ratio to baseline. Fasting serum insulin was measured in milli-international units per milliliter (mIU/mL). The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from start of randomization (week 0) to last trial-related subject-site contact (week 75).","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.73","spread":"62.3"},{"groupId":"OG001","value":"0.92","spread":"56.5"}]}]}]},{"type":"SECONDARY","title":"Change in Diastolic Blood Pressure (mmHg)","description":"Change in diastolic blood pressure from baseline (week 0) to week 68 is presented. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from start of randomization (week 0) to last trial-related subject-site contact (week 75).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3","spread":"9"},{"groupId":"OG001","value":"-1","spread":"9"}]}]}]},{"type":"SECONDARY","title":"Change in Total Cholesterol (mg/dL) - Ratio to Baseline","description":"Change in fasting total cholesterol from baseline (week 0) to week 68 is presented as ratio to baseline. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from start of randomization (week 0) to last trial-related subject-site contact (week 75).","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.96","spread":"14.8"},{"groupId":"OG001","value":"1.00","spread":"15.5"}]}]}]},{"type":"SECONDARY","title":"Change in High-density Lipoproteins (HDL) (mg/dL) - Ratio to Baseline","description":"Change in fasting HDL from baseline (week 0) to week 68 is presented as ratio to baseline. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from start of randomization (week 0) to last trial-related subject-site contact (week 75).","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.05","spread":"16.1"},{"groupId":"OG001","value":"1.02","spread":"14.9"}]}]}]},{"type":"SECONDARY","title":"Change in Low-density Lipoproteins (LDL) (mg/dL) - Ratio to Baseline","description":"Change in fasting LDL from baseline (week 0) to week 68 is presented as ratio to baseline. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from start of randomization (week 0) to last trial-related subject-site contact (week 75).","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.97","spread":"23.7"},{"groupId":"OG001","value":"1.01","spread":"25.5"}]}]}]},{"type":"SECONDARY","title":"Change in Very Low-density Lipoproteins (VLDL) (mg/dL) - Ratio to Baseline","description":"Change in fasting VLDL from baseline (week 0) to week 68 is presented as ratio to baseline. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from start of randomization (week 0) to last trial-related subject-site contact (week 75).","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.77","spread":"37.7"},{"groupId":"OG001","value":"0.92","spread":"35.2"}]}]}]},{"type":"SECONDARY","title":"Change in Free Fatty Acids (mg/dL) - Ratio to Baseline","description":"Change in fasting free fatty acids from baseline (week 0) to week 68 is presented as ratio to baseline. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from start of randomization (week 0) to last trial-related subject-site contact (week 75).","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.83","spread":"78.3"},{"groupId":"OG001","value":"0.93","spread":"70.8"}]}]}]},{"type":"SECONDARY","title":"Change in Triglycerides (mg/dL) - Ratio to Baseline","description":"Change in fasting triglycerides from baseline (week 0) to week 68 is presented as ratio to baseline. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from start of randomization (week 0) to last trial-related subject-site contact (week 75).","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.77","spread":"38.3"},{"groupId":"OG001","value":"0.92","spread":"36.2"}]}]}]},{"type":"SECONDARY","title":"Change in High Sensitivity C-Reactive Protein (hsCRP) - (mg/L) - Ratio to Baseline","description":"Change in high sensitivity C-reactive protein from baseline (week 0) to week 68 is presented as ratio to baseline. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from start of randomization (week 0) to last trial-related subject-site contact (week 75).","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.45","spread":"128.2"},{"groupId":"OG001","value":"0.84","spread":"102.5"}]}]}]},{"type":"SECONDARY","title":"Change in Plasminogen Activator Inhibitor-1 (PAI-1) Activity (AU/ml) - Ratio to Baseline","description":"Change in plasminogen activator inhibitor-1 activity from baseline (week 0) to week 68 is presented as ratio to baseline. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from start of randomization (week 0) to last trial-related subject-site contact (week 75).","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.15","spread":"86.5"},{"groupId":"OG001","value":"1.53","spread":"77.3"}]}]}]},{"type":"SECONDARY","title":"Change in Soluble Leptin Receptor (ng/mL) - Ratio to Baseline","description":"Change in soluble leptin receptor from baseline (week 0) to week 68 is presented as ratio to baseline. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from start of randomization (week 0) to last trial-related subject-site contact (week 75).","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.07","spread":"24.9"},{"groupId":"OG001","value":"1.02","spread":"22.2"}]}]}]},{"type":"SECONDARY","title":"Change in Leptin (ng/mL) - Ratio to Baseline","description":"Change in leptin from baseline (week 0) to week 68 is presented as ratio to baseline. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from start of randomization (week 0) to last trial-related subject-site contact (week 75).","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.52","spread":"75.9"},{"groupId":"OG001","value":"0.87","spread":"52.7"}]}]}]},{"type":"SECONDARY","title":"Change in Body Composition (Total Fat Mass) (%)","description":"Change in body composition (total fat mass) from baseline (week 0) to week 68 is presented. Body composition was assessed using Dual Energy X-ray Absorpmetry (DEXA). The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from start of randomization (week 0) to last trial-related subject-site contact (week 75).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.9","spread":"5.4"},{"groupId":"OG001","value":"-0.3","spread":"2.8"}]}]}]},{"type":"SECONDARY","title":"Change in Body Composition (Total Fat Mass) (kg)","description":"Change in body composition (total fat mass) from baseline (week 0) to week 68 is presented. Body composition was assessed using Dual Energy X-ray Absorpmetry (DEXA). The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from start of randomization (week 0) to last trial-related subject-site contact (week 75).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.3","spread":"8.5"},{"groupId":"OG001","value":"-1.5","spread":"5.1"}]}]}]},{"type":"SECONDARY","title":"Change in Body Composition (Lean Body Mass) (%)","description":"Change in body composition (lean body mass) from baseline (week 0) to week 68 is presented. Body composition was assessed using DEXA. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from start of randomization (week 0) to last trial-related subject-site contact (week 75).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":"5.1"},{"groupId":"OG001","value":"0.2","spread":"2.7"}]}]}]},{"type":"SECONDARY","title":"Change in Body Composition (Lean Body Mass) (kg)","description":"Change in body composition (lean body mass) from baseline (week 0) to week 68 is presented. Body composition was assessed using DEXA. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from start of randomization (week 0) to last trial-related subject-site contact (week 75).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.8","spread":"4.6"},{"groupId":"OG001","value":"-1.8","spread":"2.5"}]}]}]},{"type":"SECONDARY","title":"Change in Body Composition (Visceral Fat Mass) (%)","description":"Change in body composition (visceral fat mass) from baseline (week 0) to week 68 is presented. Body composition was assessed using DEXA. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from start of randomization (week 0) to last trial-related subject-site contact (week 75).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.2","spread":"4.4"},{"groupId":"OG001","value":"-0.1","spread":"4.5"}]}]}]},{"type":"SECONDARY","title":"Change in Body Composition (Visceral Fat Mass) (kg)","description":"Change in body composition (visceral fat mass) from baseline (week 0) to week 68 is presented. Body composition was assessed using DEXA. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from start of randomization (week 0) to last trial-related subject-site contact (week 75).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"0.3"},{"groupId":"OG001","value":"-0.1","spread":"0.3"}]}]}]},{"type":"SECONDARY","title":"Change in Body Weight (%) - DEXA Subpopulation","description":"Change in body weight from baseline (week 0) to week 68 is presented in DEXA subpopulation. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from start of randomization (week 0) to last trial-related subject-site contact (week 75).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-15.8","spread":"11.1"},{"groupId":"OG001","value":"-3.4","spread":"6.1"}]}]}]},{"type":"SECONDARY","title":"Change in Body Weight (kg) - DEXA Subpopulation","description":"Change in body weight from baseline (week 0) to week 68 is presented in DEXA subpopulation. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period: the uninterrupted time interval from start of randomization (week 0) to last trial-related subject-site contact (week 75).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-15.5","spread":"11.4"},{"groupId":"OG001","value":"-3.2","spread":"6.1"}]}]}]},{"type":"SECONDARY","title":"Participants Who Achieve \"Responder Definition Value\" (Yes/no) for SF-36 Physical Functioning Score","description":"The observed number of participants experiencing a meaningful within participant improvement in SF-36 Physical function after 68 weeks was determined based on two different thresholds. The threshold of 4.3 is the default generic responder threshold defined in SF-36 manual for a general population. The threshold of 3.7 is specific for the population with overweight or obesity included in the study and calculated using patient global rating anchor questionnaires to reflect participants' own perspective based on FDA recommendations. In the reported data, \"Yes\" infers the number of participants who have achieved an improvement in score greater than or equal to the threshold and \"No\" infers number of participants who have not achieved an improvement in score greater than or equal to the threshold. The endpoint was evaluated based on the in-trial observation period which is the uninterrupted time interval from randomization (week 0) to last trial related subject-site contact (week 75).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"318","spread":null},{"groupId":"OG001","value":"97","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"877","spread":null},{"groupId":"OG001","value":"469","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"478","spread":null},{"groupId":"OG001","value":"153","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"717","spread":null},{"groupId":"OG001","value":"413","spread":null}]}]}]},{"type":"SECONDARY","title":"Participants Who Achieve \"Responder Definition Value\" (Yes/no) for IWQoL-Lite for CT Physical Function Domain (5-items) Score","description":"The observed number of participants experiencing a meaningful within participant improvement in IWQOL-Lite-CT physical function after 68 weeks was determined based on two different thresholds. The threshold of 20 was a preliminary responder threshold based on earlier studies. The threshold of 14.6 is specific for the population with overweight or obesity included in the study and calculated using patient global rating anchor questionnaires to reflect participants' own perspective based on FDA recommendations. In the reported data, \"Yes\" infers the number of participants who have achieved an improvement in score greater than or equal to the threshold and \"No\" infers the number of participants who have not achieved an improvement in score greater than or equal to the threshold. The endpoint was evaluated based on the in-trial observation period. In trial observation period: the uninterrupted time interval from randomization (week 0) to last trial related subject-site contact (week 75).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"473","spread":null},{"groupId":"OG001","value":"145","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"720","spread":null},{"groupId":"OG001","value":"421","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"611","spread":null},{"groupId":"OG001","value":"186","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"582","spread":null},{"groupId":"OG001","value":"380","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Treatment Emergent Adverse Events (TEAEs)","description":"An adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of a product, whether or not considered related to the product. All AEs mentioned here are treatment emergent adverse events (TEAE) defined as an event for which the onset of the event occurs in the on-treatment period. The endpoint was evaluated based on the data from on-treatment observation period. On-treatment observation period: includes all time intervals in which participants are considered to be on treatment from the first (week 0) to last trial product administration (week 68), including 7 weeks of follow-up. It excludes any period of temporary treatment interruption. Temporary treatment interruption is defined as more than 7 consecutive missed doses (off-treatment period).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9658","spread":null},{"groupId":"OG001","value":"3302","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Serious Adverse Events (SAEs)","description":"A serious adverse event (SAE) is defined as any untoward medical occurrence that at any dose results in death, or is life-threatening, or requires inpatient hospitalization or causes prolongation of existing hospitalization results in persistent or significant disability/incapacity, or may have caused a congenital anomaly/birth defect, or requires intervention to prevent permanent impairment or damage. The SAEs occurred from week 0 to week 75 is presented. The endpoint was evaluated based on the data from on-treatment observation period. On-treatment observation period: includes all time intervals in which participants are considered to be on treatment from the first (week 0) to last trial product administration (week 68), including 7 weeks of follow-up. It excludes any period of temporary treatment interruption. Temporary treatment interruption is defined as more than 7 consecutive missed doses (off-treatment period).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"164","spread":null},{"groupId":"OG001","value":"53","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Pulse","description":"Change in pulse from baseline (week 0) to week 68 is presented. The endpoint was evaluated based on the data from on-treatment observation period. On-treatment observation period: includes all time intervals in which participants are considered to be on treatment from the first (week 0) to last trial product administration (week 68) including 2 weeks of follow-up. It excludes any period of temporary treatment interruption. Temporary treatment interruption is defined as more than 2 consecutive missed doses (off-treatment period).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":"10"},{"groupId":"OG001","value":"-1","spread":"10"}]}]}]},{"type":"SECONDARY","title":"Change in Amylase - Ratio to Baseline","description":"Change in amylase (measured as units per litre \\[U/L\\]) is presented as ratio to baseline. The endpoint was evaluated based on the data from on-treatment observation period. On-treatment observation period: includes all time intervals in which participants are considered to be on treatment from the first (week 0) to last trial product administration (week 68) including 2 weeks of follow-up. It excludes any period of temporary treatment interruption. Temporary treatment interruption is defined as more than 2 consecutive missed doses (off-treatment period).","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.14","spread":"21.6"},{"groupId":"OG001","value":"1.03","spread":"21.4"}]}]}]},{"type":"SECONDARY","title":"Change in Lipase - Ratio to Baseline","description":"Change in lipase (measured as units per litre \\[U/L\\]) is presented as ratio to baseline. The endpoint was evaluated based on the data from on-treatment observation period. On-treatment observation period: includes all time intervals in which participants are considered to be on treatment from the first (week 0) to last trial product administration (week 68) including 2 weeks of follow-up. It excludes any period of temporary treatment interruption. Temporary treatment interruption is defined as more than 2 consecutive missed doses (off-treatment period).","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.41","spread":"49.3"},{"groupId":"OG001","value":"0.97","spread":"37.3"}]}]}]},{"type":"SECONDARY","title":"Change in Calcitonin - Ratio to Baseline","description":"Change in calcitonin (measured as ng/L) is presented as ratio to baseline. The endpoint was evaluated based on the data from on-treatment observation period. On-treatment observation period: includes all time intervals in which participants are considered to be on treatment from the first (week 0) to last trial product administration (week 68) including 2 weeks of follow-up. It excludes any period of temporary treatment interruption. Temporary treatment interruption is defined as more than 2 consecutive missed doses (off-treatment period).","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.99","spread":"37.6"},{"groupId":"OG001","value":"0.95","spread":"40.9"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":128,"n":1306},"commonTop":["Nausea","Diarrhoea","Nasopharyngitis","Constipation","Vomiting"]}}}